Abstract
The emergence of resistance to artemisinin drugs threatens global malaria control. Resistance is widely seen in South East Asia (SEA) and Myanmar, but not comprehensively assessed in Bangladesh. This is due to lack of measuring parasite clearance times in response to drug treatment, a gold standard used to track artemisinin resistance (AR), in the Chittagong Hill Tracts (CHT), where >90% of malaria occurs in Bangladesh. Here we report delay in clinical parasite clearance half-lives > 5 h characteristic of AR, in Bandarban, a south-eastern rural, CHT district with escalating malaria and bordering Myanmar. Thirty-one and 68 malaria patients respectively presented in the clinic in 2018 and 2019, and this increase well correlated to the district-level malaria surge and rise in rainfall, humidity and temperature. A total of 27 patients with uncomplicated Plasmodium falciparum malaria mono-infection, after administration of an artemisinin combination therapy (ACT) showed median (range) parasite clearance half-life and time of 5.6 (1.5 – 9.6) and 24 (12–48) hours (h) respectively. The frequency distribution of parasite clearance half-life and time was bimodal, with a slower parasite clearance of 8 h in 20% of the participants. There was however, no detectable parasitemia 72 h after initiating ACT. Half-life clearance of > 5h, respectively seen in 35% and 40% of participants in 2018 and 2019, lacked in correlation to initial parasitemia, blood count parameters or resistance mutations of PfKelch13 (K13, the major parasite marker of AR). Culture adapted strains await assessment of in vitro resistance and new parasite determinants of AR.
Introduction
Malaria has taken a staggering historical toll on human health. However, in the 21st century many areas of the world are striving for elimination and eradication. From 2010-2018 malaria cases declined globally1. Fast acting ACTs reduced levels of infection and death due to Plasmodium falciparum, the most virulent of human malaria parasites responsible for the major burden of disease. Yet substantial global levels of malaria remain. Over 400,000 deaths and 228 million world-wide cases of malaria occurred in 20181. Global malaria levels failed to decrease in 20192. Malaria elimination in Bangladesh (where 17.5 million people live at risk for infection) made strong progress from 2010 to 2018 reducing malaria cases by 81% (http://www.nmcp.gov.bd). Over 90% of malaria cases occur in the CHTs in three districts, Khagrachhari, Rangamati and Bandarban that border Myanmar (See Fig. 1A).
A. Map of Bangladesh highlighting the malaria endemic regions with two sub-maps showing the study sites Bandarban Sadar and Alikadam Upazilla. Data provided by the National Malaria Elimination Program Bangladesh (NMEP). B. Bandarban study flow chart.
Drugs are the mainstay of treating and reducing blood stages of infection that are responsible for all the symptoms and pathologies of malaria. Resistance to drugs therefore threatens malaria control. Resistance to chloroquine arose in SEA, spread through South Asia with devastating effects for malaria morbidity/mortality in Africa 30 years ago 3. More recent spread of resistance to front line artemisinins throughout SEA and Myanmar has led to concern that there may be spread to Bangladesh which in turn may lie in the path of global dissemination of resistance 4,5 6. AR may also arise independently 7,8, suggesting multiple ways that Bangladesh parasites may become refractory to these frontline drugs for which we still have no replacements.
Resistance to artemisinins was first reported in clinical studies as a delay in clearance of early blood stage (or ‘ring’ stage) infection from patient circulation, in response to drug treatment 9,10. Subsequent studies established K13 as a molecular and major, causal marker of AR in P. falciparum malaria11,12. Studies in SEA have established strong association between polymorphisms in the β-propeller domain of K13 and delayed clearance of parasites in circulation13. Polymorphisms in K13 and additional genes associated with resistance have been characterized by the laboratory-based ring stage survival assay (RSA14), an in vitro correlate of in vivo resistance. This laboratory assay is important to prove that mutations in candidate genes when engineered into sensitive parasites in local genetic or laboratory strains are causative for resistance 15,16 as well as strains where resistance is mediated by unknown determinants17. Nonetheless, the gold standard of clinical AR remains in vivo delayed clearance.
Detection of mutations in K13 (as well as other drug resistance markers) by application of PCR based technologies to infected blood from patients is well established and widely utilized in Bangladesh 18. 19 However, measurements of in vivo delayed parasite clearance in the CHTs has not been done. A major challenge is that CHTs are remote and rural (Fig. 1A). Here we present the first report of successful adaptation and establishment of the clinical assay of delayed P. falciparum clearance at a district level hospital in the CHTs. We also established in vitro cultures of Bangladesh strains isolated from the CHTs. Data collected over 2018-2019 revealed launching these capacities to fill critical gaps in monitoring AR in the CHTs and hematological parameters, in context of sharp escalation of malaria associated with climactic factors.
Materials and Methods
Site selection to support study design
This is an ongoing prospective study for assessing in vivo parasite clearance to determine presence of clinical AR and its quantitative correlation with parasitemia, comprehensive blood count parameters, AR molecular markers as well as laboratory adaptation of patient isolates to conduct further in vitro and genetic studies of P. falciparum parasite populations in Bandarban. In 2018, we established clinical capacity to measure in vivo AR in Bandarban Sadar Hospital. The site was chosen because it is the only hospital in the CHTs where it is possible to undertake a protocol for in vivo delayed P. falciparum clearance as recommended by the Worldwide Antimalarial Resistance Network (WWARN) 20,21. For this protocol WWARN recommends obtaining multiple patient blood draws over a 72 h period. The procedure therefore necessitates clinical facilities for in-patient stay for consecutive nights. This is only available at Bandarban Sadar Hospital because it is the sole district level hospital in Bandarban District that has all the required facilities.
To reach our target number of isolates for screening of K13 polymorphisms (see sample size calculation), in 2019 we added collection of parasite isolates at Alikadam Upazilla Health Complex because of its higher annual parasitological index (API; Alikadam 21.84 in 2018, 32.13 in 2019; Bandarban-0.83 in 2018; 1.6 in 2019).
Sample size calculation
The absence of substantial information on K13 polymorphisms and no data for in vivo clearance in Bangladesh, limited local information on which to base power calculations. We therefore used findings from neighboring Myanmar, that reports 20% prevalence rate of the F446I mutation22. We assumed the same prevalence in Bandarban for all point mutations in the propeller domain of the K13 gene with 10% detected difference (precision), 80% power and 95% level of significance. On this basis, we calculated a sample size of 126 which was also expected to be within clinical capacity and existing information on patient enrollment.
Patient screening
Patients were screened when presented with positive malaria diagnosis by microscopy and/or RDT. The inclusion criteria were P. falciparum mono-infection, axillary temperature ≥37.5°C or history of fever during the past 24 h, ability and willingness to comply with the study protocol for the duration of the study, informed consent from the patient or a parent or guardian in the case of children and minimum age of children ≥1 year. The exclusion criteria included severe malaria according to the WHO definition11 i.e. organ dysfunction, multiple convulsions, impaired consciousness. The exclusion criteria additionally included severe malnutrition, anemia (Hb <8g/dL), self-administered antimalarial or antibiotics before enrollment or pregnancy.
Parasite clearance study procedure
Prior to administration of the first dose of Artemether-lumefantrine combination therapy (ACT) called KOMEFAN 140 (Mylan Laboratories Ltd., India), the initial parasite density and speciation was counted against 200 white blood cells (WBC; thick smear) or 2000 RBC (thin smear with duplicate slides stained with Giemsa (Merck, Germany). The smears were counted in duplicates by two independent microscopists and then averaged. Parasite density/ml was calculated by dividing the number of asexual parasites by the number of WBC counted (200) and multiplying by an assumed WBC count of 8,000/ l in thick film (or thin film, if the thick film was >250 parasites/50 WBC). Smears were considered negative when no asexual parasites were found after counting 200 WBC.
The admitted IPD (Indoor Patient Department) patients were treated by the hospital staff as per the protocol of the National Malaria Elimination Program. Briefly, one to four tablets (depending on patient’s body weight) of KOMEFAN 140 (containing 20 mg Artemether and 120 mg Lumefantrine), was administered at each of the following six time points 0 h, 8 h, 24 h, 36 h, 48 h, 60 h 72h. Blood draws were planned at 6, 12, 24, 36 and 48 h post first drug administration 20. Due to logistical difficulties, at the outset, the 12 and 24 h time points were respectively replaced by 18 and 36 h. However, some patients showed rapid reduction of parasites in the 12 h interval between 6 h and 18 h which limited fitting to curve. For this reason, the first four blood draws were undertaken every 6 h after administration of the first ACT (namely, 6, 12, 18, 24 h), followed by a time point every 12 h at 36, 48, 60, 72 h.
Patients were confirmed to be free of parasites and fever for at least one day and up to 72 h prior to being released from the clinic. Smears were considered negative when no asexual parasites were found after counting 200 WBC or 2000 RBCs. Patients were subsequently followed up for fever, pulse and blood pressure and malarial infection (by RDT and slides) up to 30 days at home weekly on day 9, 16, 23 and 30. No abnormalities were found. The study had no influence on the treatment decisions made by the hospital physicians.
Analyses of parasite clearance data
Parasite clearance times (PCTs) were determined for each patient using the WWARN parasite clearance estimator (PCE) tool21. The parasite clearance half-life was determined by plotting serial parasite counts on the parasite clearance estimator tool by WWARN 20,21. The following parameters were defined: Clearance rate constant: the fraction by which parasite count falls per unit time. Slope half-life: Estimated time in hours it takes for the parasitaemia to decrease by half (50%), independent of initial parasite density. PC50, 90, 95 and 99: Estimated time in hours for parasitaemia to be reduced by 50%, 90%, 95% and 99% of its initial value (initial parasite density) respectively. All definitions above follow WWARN methodology for calculating parasite clearance 20,21.
Blood cell assessment
Sysmex XP-300 Haematology Analyser (Sysmex Corporation, Kobe, Japan) was used to provide a full blood cell count including differential white blood cell counts, prior to administration of the ACT.
Culture adaptation of patient isolates
10ml venous blood was drawn before administrating ACT from adults (≥18 years of age) and 7ml from adolescents (ages 11-17) using K2EDTA vacutainers (7.2 mg; 4.0 mL; Becton Dickinsonâ, Erem-bodegem, Belgium). Most of the bulk amount of parasitized venous blood committed to culture adaptation was washed, resuspended to 4% hematocrit with freshly washed uninfected red blood cells in 5ml RPMI 1640 medium containing L-glutamine, 50 mg/liter hypoxanthine, 25mM HEPES, 2g/liter glucose, 20 μg/ml gentamicin, 0.225% NaHCO3 and 15% human pooled plasma with 0.5% Albumax. The suspension was introduced into a culture flask placed in a candle jar (gas conditions: 5% CO2, 5–10% O2 and 85–90% N2) which in turn was placed in an incubator at 37° C. Culture media was changed and thin smears with Giemsa were made every day. When the parasitemia reached 2% rings, the cultures were frozen for storage. The times to reach 2% was noted. An adaptation was considered unsuccessful if no parasites emerged upto 60 days.
DNA extraction
Genomic DNA was extracted from 200 µl whole blood using the QiaAmp blood mini kit (QIAGEN, Inc., Germany) according to the manufacturer’s instructions. 500ul of patient whole blood was cryopreserved for future experiments.
Species confirmation by genotyping
Malaria species was confirmed by using nested PCR method following previously published method with minor modifications 19.
K13 propeller domain sequence
The sequence of the propeller domain of kelch13 gene was amplified by nested PCR adapted from previously described procedures11,19 An 849 bp product was amplified by ExoSAP-IT (Affymetrix). Amplified products were sequenced using the Sanger sequencing method on an ABI 3500 Genetic Analyzer (Life Technologies, USA). Sequencing primers: K13_N1_F: 5’-GCC AAG CTG CCA TTC ATT TG – 3’, K13_N1_R: 5’ – GCC TTG TTG AAA GAA GCA GA -3’. Both forward and reverse strands were aligned against P. falciparum 3D7 strain (PF3D7_1343700, PlasmoDB Release 46) using CLC sequence Viewer 8 (QIAGEN Aarhus A/S).
Weather data
Weather data for 2018 and 2019 was obtained from Soil Resource Development Institute (SDRI), Bandarban, Bangladesh.
Ethical approval
The study was approved by the Ethical Review Committee of icddr,b (Protocol # PR-17078) and the Institutional Review Board of the University of Notre Dame (Protocol # 17-10-4146).
Maps
ArcGIS 10.4.1 (ESRI Inc., Redlands, CA) was used to generate malaria incidence map for 2019.
Statistical analysis
Associations between two variables were assessed using Spearman correlation and Mann-Whitney analysis. All statistical analyses were performed using GraphPad Prism 7 (GraphPad Software, La Jolla, CA).
Results
Overall Clinical Presentation Profiles
As indicated earlier, in vivo parasite clearance studies in Bandarban Sadar Hospital were undertaken over two years from 2018-2019 (Fig. 1). In 2018, of 31 patients who presented with malaria symptoms, 17 were excluded because they were either infected or co-infected with P. vivax, showed severe malaria, were anemic or pregnant, had recent prior exposure to antimalarials, refused to consent or were rapid diagnostic test negative despite having malaria symptoms (also summarized in Fig. 1B). Of the 14 with P. falciparum mono-infections, 9 were enrolled in PCT studies. The remaining 5 showed initial parasitemias below 1000 parasites/µl, the threshold level for inclusion in PCT measurements. However, all 14 were subjected to K13 marker analyses and hematological assessments. In 2019, of 68 patients who presented with malaria symptoms, 27 met inclusion criteria of P. falciparum mono-infection without additional factors. 18 who showed initial parasitemia ≥ 1000 parasites/µl were enrolled in PCT studies (but all 27 were included in K13 and hematological analyses).
Together the data in Fig. 1 suggested that although P. falciparum infections were dominant, only about a third could be utilized for PCT studies due to other complications of presentations or insufficient threshold parasitemia. One unexpected observation was that the number of malaria patients presenting at the clinic increased by ∼2 fold from 2018 to 2019 (Fig. 1B). We took this in context that many levels of vector borne diseases like malaria can be affected by climate and Bangladesh is known to be vulnerable to climate change. As shown in Fig. 2A, monthly presentation of malaria patients in the clinic, closely corresponded with the monthly parasite incidence levels in the district (Spearman correlation coefficient, ρ = 0.8804, p < 0.0001) which in turn showed significant correlation to rainfall (Spearman co-efficient, ρ = 0.73, p < 0.0001 (Figure 2B), humidity (Spearman co-efficient, ρ = 0.91, p < 0.0001) and minimum temperature (Spearman co-efficient, ρ = 0.72, p = 0.0001) seen in Bandarban (Fig. 2C). This strongly suggested that the two-fold increase seen in presenting patients in 2019 was due to higher levels of malaria in the district rather than other determinants affecting access and care.
A. Total monthly malaria cases in Bandarban Sadar Hospital (purple line) and Bandarban district (bars). Spearman co-efficient, ρ = 0.8804, p < 0.0001; B. Total monthly malaria cases (bars) and rainfall (red line) in district, Spearman co-efficient, ρ = 0.73, p < 0.0001; C. Total district monthly malaria cases and maximum average temperature distribution (grey squares), Spearman co-efficient, ρ = -0.12, p = 0.58; minimum average temperature (blue triangles), Spearman co-efficient, ρ = 0.72, p = 0.0001; average humidity (green triangles), Spearman co-efficient, ρ = 0.91, p < 0.0001. Annual parasite index (API) in Bandarban Sadar was 0.83 (population at risk, n= 152,915) in 2018 and 1.60 (population at risk, n= 156738) in 2019.
Participants enrolled in PCT studies were young adults with 67% males (Table 1). At time of presentation, all but one had fever (≥ 37.5°C) and none were significantly anemic (hemoglobin < 9 g/dl for females and 10 g/dl for males) (Table 1, Supplementary Table 1 and Supporting Information SI). All participants tolerated and complied with study procedures. No serious adverse events were reported. Mild to moderate adverse events of headache, body aches, nausea, vomiting, fever or chill were observed and recorded for each participant. They were related to acute malaria illness and resolved within 72 h /3 days. Participants did not receive acetaminophen or other anti-pyretics after the first dose of the ACT KOMEFAN 140.
Presenting clinical characteristics and parameters of participants enrolled in PCT studies in Bandarban District Hospital Sadar, 2018 - 2019. (See also Supplementary Table 1).
Clinical Outcomes and Parasite Clearance
Enrollment parasite densities were moderate in each year (Table 1). Over two years, the geometric mean was 20020/µl; 95% confidence interval 9,840 – 116,875 /µl. The median time to fever clearance was 24 with a range of (24 to 48 h; not shown). The aggregate of all data points were included in measurement of parasite clearance time independent of initial parasitemia (Fig. 3A; Table 2). Over the 27 patients, the median (range) parasite clearance half-life and time was 5.57 (1.5 – 9.6) and 24 (12–48) h, respectively. The median (range) parasite clearance half-life of patients enrolled in 2018 and 2019 was 3.1 (1.5 – 4.8) h and 6.98 (2.86 – 9.6) h respectively (Table 2; Supplemental Fig. S2A and S2B). Parasite clearance estimation profiles of individual patients with 50% clearance rates of > 5h are provided in Supplemental figure S1. Lag-phase in parasite clearance was detected in 8 out of 10 patients with delayed 50% clearance. Parasite clearance half-life based on the initial value and the time required to reach 50%, 90% and 95% (PC50, PC90, and PC95) are summarized in Table 2. All parasite infections were cleared by 72 h /3 days after starting treatment (Fig. 3B-C).
Parasite clearance data, median (IQR) (range) of study participants in 2018 and 2019.
A. Parasite clearance curve showing linear regression of percent parasite density in vivo over time (hours) B. Cumulative proportion of parasitemic participants and their clearance over a 30 day period (follow-up on day 9, 16, 23 and 30) C. Cumulative proportion of parasitemic participants and their clearance over 72 hours after administration of first dose of ACT D. Proportion distribution of participants with time (hours) of first negative microscopy slide after administration of first dose of ACT E. Percentage of patients with of clearance rate constant (per hour) F. Proportion of participants with associated PC50 values, samples collected in 2018 G. Proportion of participants with associated PC50 values, samples collected in 2019 H. Percentage of participants with delayed in vivo clearance (PC50) in 2018 and 2019. (See also Supplementary Figure S2).
Since the number of participants were different in 2018 and 2019, we examined the proportion of participants as a function of the time in hours to a ‘slide-negative’ state to confirm that clearance was achieved by 60 h (Fig. 3C; Supplementary Fig. S2 C-D). While most patients in 2018 and 2019 reported complete parasite clearance within 48 h in 2018 and 2019; one patient reported 54h to clear all parasites, the longest time recorded for complete parasite clearance in this study (Supplemental Fig. S2 E-H). Histograms of number of participants and their clearance constant rate/hour (Fig 3D-E) suggested the highest number of participants (34%) having a clearance constant rate of 0.30/h, followed by 11% of participants having a clearance constant rate of 0.45/h, the second highest percentage of participants. Analyses of the proportion of parasites as a function of PC50 also supported a bimodal distribution (Fig. 3F-G) This included the expected fast clearing parasites that reach median 50% density by 3 (2.0-4.0) h, but in addition, approximately 20% of parasites showed a slower median clearance half-life of 8 (6-10) h. This was more marked in 2019 compared to 2018. The proportion of participants per year with PCT >0.5 increased from ∼ 34% to 40% from 2018 to 2019, with 38% of patients having median 50% parasite clearance of 8.4 (7.6 – 10.2) h in 2019. Together these data suggest that in vivo delayed clearing P. falciparum was reliably detected in two consecutive years, 2018 and 2019. Moreover, although the number of P. falciparum infection levels increased ∼2 fold, the fraction of slow clearing in 2019 was comparable to that in 2018. Nonetheless, all infections were cured, indicating that there was no failure of ACT KOMEFAN.
We subsequently undertook regression analyses to understand parasite and host factors that may influence parasite clearance. As shown in Fig. 4, there was no major association between PC50 and potential modifiers including age, gender and initial parasite density in either 2018 or 2019. Additionally, regression analyses failed to yield high-confidence associations between PC50 and initial mean corpuscular volume (MCV) mean corpuscular hemoglobin concentration (MCHC), mean corpuscular hemoglobin (MCH) white blood cells-total count (WBC/TC), mixed cell count (MXD)-monocytes– basophils–eosinophils and platelets (Fig. 5). Regression and correlation analyses, median values and range for all parameters are respectively shown in Fig. 5, and Table 3. Regression and correlation analyses between initial parasite density and hematological parameters also failed to show high-confidence associations (Supplemental Fig. S3). Together the data in Figs. 4, 5, Supplemental Fig. S3 and Table 3, suggest that initial parasitemia and blood count parameters did not make substantial contribution to in vivo delayed clearance phenotype. Patient hematological readouts are provided in Supplementary Table 2 and Supporting Information (SI)
Presenting hematological and immune cell characteristics of participants enrolled in PCT studies in Bandarban District Hospital, Sadar, 2018 -2019. (See also Supplementary Table 2).
A. Age of study participants, Spearman co-efficient, ρ = -0.026, p= 0.89, R2 = 0.00096 B. Mann-Whitney test of PC50 between male and female participants, p= 0.17 C. Initial parasite density, samples collected in 2018, Spearman co-efficient, ρ = 0.63, p= 0.076, R2 = 0.04 D. Initial parasite density, samples collected in 2018, Spearman co-efficient, ρ = 0.27, p= 0.28, R2 = 0.017 E. Initial parasite density, samples collected in 2018 and 2019, Spearman co-efficient ρ = 0.37, p= 0.054. R2 = 0.016
A. Hemoglobin % (g/dL), Spearman co-efficient, ρ = 0.4, p= 0.04, R2 = 0.08 B. Platelets (µl), Spearman co-efficient, ρ = -0.13, p= 0.52, R2 = 0.02 C. Mean corpuscular volume (MCV) (fl), Spearman co-efficient, ρ = 0.03, p= 0.8, R2 = 0.005 D. Mean corpuscular hemoglobin MCH (pg), Spearman co-efficient, ρ = -0.015, p= 0.08, R2 = 0.03 E. Mean corpuscular hemoglobin concentration MCHC (g/dL), Spearman co-efficient, ρ = -0.19, p= 0.3, R2 = 0.05 F. White blood cells-total count (WBC/TC) (µl), Spearman co-efficient, ρ = 0.37, p= 0.05, R2 = 0.2 G. Lymphocytes (%), Spearman co-efficient, ρ = 0.38, p= 0.04, R2 = 0.08 H. Neutrophils (%), Spearman co-efficient, ρ = 0.48, p= 0.01, R2 = 0.15 I. Mixed cell count (MXD)-monocytes– basophils–eosinophils (%), Spearman co-efficient, ρ = -0.32, p= 0.4, R2 = 0.08
K13 polymorphisms
Since comprehensive assessment of K13 polymorphisms in Bangladesh is not yet available, we used polymorphisms in neighboring Myanmar as the best guide for power calculations. F446I has been reported at 20% prevalence in Myanmar 22, based on which we projected requirement for collecting 126 isolates for our studies. In 2018, low numbers of patients were enrolled in Bandarban Sadar due to low levels of malaria in the area. Because of this in 2019, we added collection of parasites in Alikadam Upazilla Health Complex where the API was more than ten-fold higher than in Bandarban Sadar.
As summarized in Fig. 6 A-B, samples were collected from a total of 86 patients with acute P. falciparum mono-infection without severe manifestation were enrolled in Alikadam. Participants ranged from pediatric to young adults. 63% and 75% were males in 2019 and 2020 respectively. Parasite densities were moderate (2018 geometric mean, 22,460/μl; 95% confidence interval 4,860 – 35,850; 2019 geometric mean, 45,000// l; 95% confidence interval 4480-145,000) and patients were not anemic (Hb<9 g/dl). Since K13 polymorphisms associated with AR are invariably associated with β-propeller domain, we restricted analyses to this region. As shown in Fig. 6C, there were no polymorphisms identified in Bandarban Sadar. One polymorphism K13A578S was detected in Alikadam. Prior studies have reported K13A578S which is known to be a sensitive mutation, in the CHT18. Together these findings suggest that in vivo delayed clearance cannot be explained by resistance mutations in the β-propeller domain of K13.
A. Alikadam study flow chart. B. Baseline characteristics, parasite clearance and incidence parameters in participants enrolled in Alikadam Upazilla Health Complex (UHC) in 2019 and 2020. C. k13 polymorphisms in Bandarban Sadar and Alikadam Upazilla.
Culture adaptation
Studies in SEA established strong association between polymorphisms in the β propeller domain of K13 and delayed clearance of parasites in circulation. However, polymorphisms in additional genes have also been associated and shown to be causal for resistance as determined in the laboratory-based ring stage survival assay (RSA) 14,16,15. As summarized in Fig 7A, we culture adapted 7 of 9 isolates obtained in 2018 and one of 18 in 2019. The range of initial parasitemia varied from 0.06% to 3.9%. Nonetheless 2% parasitemia was achieved within 9-12 days. In 2018, >75% of isolates were successfully adapted. However, in 2019, only one isolate (5%) could be adapted. The reasons for this variability in culture adaptation remain unclear and need to be explored in further studies.
A. Flow chart of laboratory culture adaptation attempt in 2018 and 2019. B. Isolates and their initial parasitemia and days taken to reach adaptation
Discussion
The goal of Bangladesh’s national strategic plan for malaria 2017–2021 is to eliminate the disease by 203023. A key component of the plan is to prevent emergence of P. falciparum strains resistant to artemisinins. This needs to be accomplished in addition to interrupting local transmission, and preventing reestablishment of infection. Measuring in vivo delayed clearance of parasites in response to ACT treatment in malaria patients and establishment of culture-adapted Bangladesh strains to determine parasite-intrinsic resistance, are both critically important to guide strategies and interventions to achieve and sustain elimination. It will be imperative to understand whether one or both expand over time. Hence this study fills an important gap in knowledge and approaches to identifying emergence of AR in the CHTs where >90% of malaria occurs in Bangladesh.
From 2018-2019 malaria had an average of 60% resurgence across Bandarban. Infections rose in the low-API sub-district of Bandarban Sadar as well as Alikadam, with high API. The increase was well correlated with climatic factors, suggesting it may be due to increasing local transmission which is a malaria control priority that must be considered in conjunction of emerging AR24. Previous studies have reported on analyses of K13 polymorphisms in Bangladesh18. A single study13 reported median (range) parasite clearance half-life of 2.5 (0.7 to 5.4) in Ramu in Cox’s Bazar (where malaria incidence is low) but not in the Hill Tracts. Nor did they establish culture adaptation of Bangladesh strains, which is important, since Bangladesh strains appear to be genetically separable from SEA and Indian strains 25 and AR is known to be P. falciparum strain dependent. In our study, the clinical presentation of malaria in the Bandarban Sadar Hospital was representative of overall malaria levels and their escalation in the district, suggesting the findings have implications for the entire district and possibly the CHT. We report presentations of P. vivax, co-infection of P. vivax and P. falciparum as well as P. falciparum-induced severe disease, with substantial increase in severe disease in 2019. Consistent with prior reports 26 P. falciparum caused ∼80-90% of infections in Bandarban. However, acute, uncomplicated, mono-infection by P. falciparum represented 45% and 39% of patients in 2018 and 2019 respectively and only about two thirds of those had parasite densities >1000/µl.
We detected delay in ‘ring’ parasite clearance half-life > 5 h, a characteristic for AR in Bandarban. Rings are the parasite stage in the circulation and can be readily detected in a blood draw. 35-50% of enrolled patients showed delay in parasite clearance half-life for two consecutive years. Initial parasite densities > 1000 parasites /µl and time points taken every 6 hours for first 24 h after the administration of first ACT dose were critical to analyzing the data using the WWARN PCE tool. At the outset of the study, after the first draw at 6 h subsequent time points were spaced 12h apart in the first 24-30 h. But only 60% of these collections could be evaluated by the PCE tool. Upon correction to every 6 h, 100% of collections yielded interpretable data.
Across 27 patients, the median parasite clearance half-life was 5.6 h, but as many as a fifth showed much greater delayed clearance half-life of 8h. Nonetheless there was no evidence of drug failure either during the first 72h in the clinic or the following 30 days at home. This suggested that while there may be a delay in clearing rings, later stage parasites were effectively eliminated due to activity of the long lived partner drug and that the ACT is still effective. This is in contrast to Cambodia, Thailand and Vietnam where ACT combinations have lost efficacy 6,27,28. There was no correlation between the time to 50% of the initial parasite density (PC50) and initial parasitemia or blood cell counts. Notably, although platelet levels were significantly reduced relative to parasitemia (not shown) they showed no correction with PC50. In the case of initial Hb, lymphocytes and neutrophils, although the correlation coefficient was low (< 0.6), the p values were < 0.05, suggesting there may be weak correlation to further evaluate in subsequent studies. In prior work, correlates of immunity has been inversely correlated with delayed clearance 29. In future studies, measuring blood cell count every six hours during the first 24 h of parasite clearance, is expected to capture data most pertinent to the window for in vivo parasite delayed clearance.
A single K13 polymorphism associated with sensitive parasites was detected, suggesting that the observed in vivo delayed parasite clearance characteristic of AR cannot be due to a resistance mutation in K13. Further K13 resistance polymorphisms in Bandarban have not expanded to the extent (∼20%) reported in Myanmar. Establishment of parasites adapted for culture greatly facilitates understanding whether parasites that show delayed in vivo delayed clearance are also resistant in vitro (as measured by the RSA that evaluates ring stage resistance) laying the ground work to identify new parasite determinants of resistance. To the best of our knowledge this is the first report of culture adaptation of Bangladeshi parasites. A high level of success was achieved in 2018, when 7 out 9 isolates were successfully adapted. In 2019 only one (of 18) was culture adapted. The reasons remain unclear but one possibility is that because of the increase in malaria incidence, there were higher levels of long lived partner drugs in the circulation of the patient in 2019 and that compromised lab-adaptation. To address this issue, future studies need to include measurements of the concentration of partner drug after in vivo blood collection.
Since the Alikadam sub-district clinic facility lacks facilities for overnight stay, in vivo parasite clearance measurements were not undertaken there. But Alikadam was selected as a second site because it has a sub-district clinic (Alikadam Upazilla Health Complex, with 30 beds to monitor day patients) and its API was much higher than that of Bandarban (21.4 compared to 0.83 in 2018 and 32.13 compared to 1.60 in 2019). It is also closer to the border with Myanmar, where K13 resistance mutations have been reported. Work in Alikadam enabled rapid expansion of collection of infected blood samples for analyses of K13 polymorphisms and adapting Bangladeshi parasites into cultures. Building the requisite clinical capacity for overnight stay and in vivo parasite clearance studies will render Alikadam as a superior sub-district site for in vivo delayed clearance studies. This will also provide a model to expand to other sub-districts in Bandarban and the CHT, to broaden the assessment clinical AR across remote rural, forested regions with low population density, that present the major frontier of malaria in Bangladesh.
Conclusions
We have established for the first time, capacity to measure in vivo parasite clearance times in response to drug treatment, a gold standard used to track AR, culture adaptation of Bangladeshi parasite strains and a model to expand both clinical and laboratory studies in remote, rural areas of Bangladesh that have the greatest concentration of malaria. We report clinical parasite clearance half-life > 5 h characteristic of AR, and culture adaptation of Bangladesh strains that empowers future laboratory analyses to determine whether clinical AR in Bandarban is an intrinsic parasite property as well as underlying new parasite determinants.
Data Availability
All data utilized are included in the manuscript and can be found in the associated tables, figures, supplementary tables and figures
Author Contributions
MKN. Conceptualization, study design, establishment and supervisor of field lab, adaptation of filed strains to in vitro cultures curation and analyses of all data, visualization of results, drafting and editing of manuscript.
SAS. Supervision of field lab at both the sites, in vitro culture maintenance and establishment, and data curation
AM. Conceptualization, adaptation of field strains to in vitro cultures, curation and analyses of all data, visualization of results, drafting and editing of manuscript.
MRHH. Supervision of field lab in Bandarban Sadar, data curation, in vitro culture maintenance, and establishment.
CSP. Clinical supervision and monitoring, and data curation
FTJ. Diagnostic PCR, K13 sequencing, and data curation.
IS. Statistical analyses and support, visualization of results and data curation.
AS. Management information systems specialist support for database support.
ASK. Study site supervision and facilitation.
RW. Conceptualization and design of blood cell count analyses, data curation and manuscript editing.
NM. Conceptualization and design of blood cell count analyses, data curation and manuscript editing.
ASM. Study supervision and facilitation (civil surgeon of Bandarban).
BC. Clinical Protocol Review and Approval University of Notre Dame.
RH. Co-investigator, study supervision
WAK. Co-investigator, study supervision
Md S. A. Field site Principal Investigator, conceptualization and project supervision, design and development of research plan, data analyses, drafting and editing of manuscript.
KH. Principal Investigator, overall conceptualization and project supervision, design and development of research plan; curation and analyses of all data, visualization of results; drafting and editing of manuscript, funding acquisition.
Supplementary Tables and Figures
Participant age range, febrile status, parasite density (per µl), parasitemia (%) and hemoglobin (g/dl) at time of enrollment in the study in Bandarban District Hospital, Sadar, 2018 -2019.
Hematological: reticulocytes (%), platelets (per µl), mean corpuscular volume (fl), mean corpuscular hemoglobin (pg), mean corpuscular hemoglobin concentration (g/dL) and immune cell characteristics (whole blood cell total count (per µl), lymphocytes (%), neutrophils (%) and monocytes-basophils-eosinophils (%) of participants enrolled in the study in Bandarban District Hospital, Sadar, 2018 -2019.
Supplementary Figures
At t=0, smears were made prior to drug administration. Panels A-L show individual WWARN plots of patients with the half-life parasite clearance exceeding 5h. Green circle: projected zero parasitemia set at log 4 to fit Tobit regression model (Flegg et al. 2011). Grey circle: Indicating a measure in lag phase, which in panel A, is shown by the red line.
Linear regression analyses of parasite clearance times and percent parasite density in vivo over time (h), A. 2018 and B. 2019. Cumulative proportion of parasitemic participants and timing of their clearance of parasites over a 30 day period (follow-up on day 9, 16, 23 and 30) C. 2018 and D. 2019. Cumulative proportion of parasitemic participants and timing of their clearance of parasites over 72 h after administration of first dose of ACT, E. 2018 F. 2019. G-H. Proportion of participants versus time (h) for first negative microscopy slide after administration of first dose of ACT in G. 2018 and H. 2019
Linear regression and correlation analyses between initial parasite density (parasites/µl) and A. Platelets, Spearman co-efficient, ρ = -0.35, p= 0.02, R2 = 0.04. B. Mean corpuscular volume (MCV), Spearman co-efficient, ρ = 0.2, p= 0.2. R2 = 0.036 C. Mean corpuscular hemoglobin (MCH), Spearman co-efficient, ρ = 0.3, p= 0.1. R2 = 0.04. D. Mean corpuscular hemoglobin concentration (MCHC), Spearman co-efficient, ρ = 0.3, p= 0.04, R2 = 0.03. E. White blood cell-total count (WBC/TC), Spearman co-efficient, ρ = -0.2, p= 0.17, R2 = no fit. F. Lymphocytes, Spearman co-efficient, ρ = -0.2, p= 0.2, R2 = 0.11. G. Neutrophils, Spearman co-efficient, ρ = 0.17, p= 0.3, R2 = 0.1. H. Mixed cell count (MXD)-monocyte–basophil–eosinophil, Spearman co-efficient, ρ = -0.03, p= 0.8, R2 = 0.008
Acknowledgments
This work was supported by the University of Notre Dame, Keough School for Global Affairs, Notre Dame Research and the Provost Office as well as National Institutes of Health USA, R01 HL 1330330 (KH). We are grateful to the study participants. We thank Dr. Mathew Sisk (Hesburgh Libraries, University of Notre Dame) for assisting in creating the incidence map of Bangladesh. We thank Dr. Arjen Dondorp (Mahidol Oxford Tropical Medicine Research Unit) for helpful discussions. We thank the Soil Resource Development Institute (SRDI), Bandarban for weather data. icddr,b acknowledges with gratitude the commitment of University of Notre Dame to its research efforts. icddr,b is also grateful to the Governments of Bangladesh, Canada, Sweden, and the UK for providing core/unrestricted support.
References Cited
